Cargando…
Pramlintide in the Management of Insulin-Using Patients with Type 2 and Type 1 Diabetes
In patients with diabetes, dysregulation of multiple glucoregulatory hormones results in chronic hyperglycemia and an array of associated microvascular and macrovascular complications. Optimization of glycemic control, both overall (glycosylated hemoglobin [A1C]) and in the postprandial period, may...
Autores principales: | Pullman, John, Darsow, Tamara, Frias, Juan P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1993989/ https://www.ncbi.nlm.nih.gov/pubmed/17326327 |
Ejemplares similares
-
Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes
por: Ryan, Gina, et al.
Publicado: (2009) -
Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes
por: Riddle, Matthew, et al.
Publicado: (2009) -
Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes
por: Riddle, M. C., et al.
Publicado: (2015) -
Ultra‐Fast Insulin–Pramlintide Co‐Formulation for Improved Glucose Management in Diabetic Rats
por: Maikawa, Caitlin L., et al.
Publicado: (2021) -
Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis
por: Qiao, Yong-Chao, et al.
Publicado: (2017)